Afficher la notice abrégée

Two-year results from a global observational study investigating proactive dosing regimens with intravitreal aflibercept in neovascular age-related macular degeneration (nAMD) in routine clinical practice: the XTEND study

dc.rights.licenseopenen_US
dc.contributor.authorBAILEY, Clare C.
dc.contributor.authorCHAUDHARY, Varun
dc.contributor.authorMITCHELL, Paul
dc.contributor.authorKANG, Se Woong
dc.contributor.authorTADAYONI, Ramin
dc.contributor.authorALLMEIER, Helmut
dc.contributor.authorLEE, JinKyung
dc.contributor.authorZHANG, Xin
dc.contributor.authorMACHEWITZ, Tobias
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535
IDREF: 028739272
dc.date.accessioned2023-12-13T10:33:57Z
dc.date.available2023-12-13T10:33:57Z
dc.date.issued2023-06
dc.identifier.issn0146-0404en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/186591
dc.description.abstractEnPurpose : The 36-month XTEND (NCT03939767) multicenter, observational, prospective study examined the effectiveness of proactive treatment regimens of intravitreal aflibercept (IVT-AFL) in treatment-naïve patients with nAMD in routine clinical practice. Fourteen countries with European Medicines Agency (EMA)-aligned and three countries with non-EMA-aligned labels were included. Methods : Patients aged ≥50 years with nAMD were eligible if planned to receive 2 mg IVT-AFL according to the approved label. The label-specified regimens were EMA-aligned (8-week minimum treatment interval in Year 1 after three initial monthly IVT-AFL injections), or non-EMA-aligned (4-week minimum treatment interval in Year 1 after three initial monthly IVT-AFL injections). Treatment intervals could be extended in 2-/4-weekly increments to a maximum of 12/16 weeks. Primary endpoint was mean change from baseline in best-corrected visual acuity (BCVA), Early Treatment Diabetic Retinopathy Study letters at Month 12. Statistics were descriptive. Results : We present 2-year results from the ongoing XTEND study, which coincided with the peak of the COVID-19 pandemic. In total, 1466 patients (mean age 79 years, 61% female) were included. Results were consistent across both labels, and overall results are presented. The majority (88%) of patients were intended to receive a treat-and-extend regimen; proactive fixed-dosing regimen was planned for the remaining patients. From baseline (BL) (mean±SD: 54.3±20.3 letters), mean change (95% CI) in BCVA was +4.3 (3.4, 5.3) letters after 1 year, and +2.3 (1.3, 3.3) letters after 2 years. In patients who had a mean BL BCVA ≥70 letters (75.0±5.0), vision was maintained after 1 and 2 years (74.3±12.0 and 72.0±15.1). Patients received a mean±SD of 7.7±2.7 IVT-AFL injections over 1 year and 10.8±5.0 injections over 2 years. Mean±SD change from BL in central retinal thickness was −106±129 μm during 1 year and −109±130 μm during 2 years. No new safety concerns were identified. Conclusions : In the XTEND study, the majority of patients achieved and maintained robust functional and anatomic improvements. For patients who had a BL BCVA ≥70 letters, BCVA was maintained above 70 letters during the first 2 years of the ongoing 3-year study. This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.
dc.language.isoENen_US
dc.title.enTwo-year results from a global observational study investigating proactive dosing regimens with intravitreal aflibercept in neovascular age-related macular degeneration (nAMD) in routine clinical practice: the XTEND study
dc.title.alternativeInvest Ophth Vis Scien_US
dc.typeArticle de revueen_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.journalInvestigative Ophthalmology & Visual Scienceen_US
bordeaux.page3en_US
bordeaux.volume64en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue8en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04341956
hal.version1
hal.date.transferred2023-12-13T10:33:59Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Investigative%20Ophthalmology%20&%20Visual%20Science&rft.date=2023-06&rft.volume=64&rft.issue=8&rft.spage=3&rft.epage=3&rft.eissn=0146-0404&rft.issn=0146-0404&rft.au=BAILEY,%20Clare%20C.&CHAUDHARY,%20Varun&MITCHELL,%20Paul&KANG,%20Se%20Woong&TADAYONI,%20Ramin&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée